Research and Clinical Trials

Clinical Trial of Ceftriaxone in Subjects with ALS
Brief Description  
The objective of this study are to determine the pharmacokinetics and tolerability of long term ceftriaxone treatment and to subsequently determine the efficacy of this treatment in subjects with ALS.
Who may be Eligible  
  • Participants with familial or sporadic ALS
  • Age 18 years or older
  • Women must not be able to become pregnant (e.g. post menopausal, surgically sterile, or using adequate birth control methods) for the duration of the study.
  • Women of childbearing potential must have a negative pregnancy test at screening and be nonlactating.
  • First ALS symptoms occurred no more than 3 years prior to screening visit.
  • Not taking riluzole, or on a stable dosage for at least thirty days prior to the screening visit.
  • Subject has a competent caregiver who can and will be responsible for administration of study drug. If there is no caregiver, another qualified individual must be available to administer the study drug.
  • Subjects medically able to undergo placement of central venous catheter as determined by the investigator
IRB Number  
Principal Investigator  
Bravver, Elena

For More Information, Contact  Jaime  , Shue
Phone:  (704) 446-1900  Fax:  (704) 446-6802  
Address:1010 Edgehill Road North Charlotte, NC 28207